HISUN(SH:600267)2025-10-27 12:05Financial Performance - The company's revenue for the third quarter reached ¥2,672,459,633.39, an increase of 1.57% compared to the same period last year[4] - Total profit for the quarter was ¥215,434,956.96, representing a significant increase of 79.59% year-over-year[4] - Net profit attributable to shareholders was ¥161,858,607.96, up 102.14% compared to the same quarter last year[4] - The net profit excluding non-recurring gains and losses for the quarter was ¥169,287,578.00, reflecting a 96.13% increase year-over-year, driven by growth in sales of formulations and animal drugs[4][9] - Basic earnings per share for the quarter was ¥0.14, a 100% increase compared to the same period last year[4] - Total operating revenue for the first three quarters of 2025 reached ¥7,922,794,186.82, a slight increase from ¥7,874,540,640.41 in the same period of 2024, representing a growth of approximately 0.61%[23] - Net profit for the first three quarters of 2025 was ¥468,057,810.10, down from ¥510,285,014.19 in 2024, reflecting a decline of approximately 8.27%[24] - Total revenue for the first three quarters of 2025 reached ¥8,563,322,286.31, an increase from ¥8,365,256,571.78 in the same period of 2024, reflecting a growth of approximately 2.4%[27] - Basic and diluted earnings per share for the current period were both ¥0.40, down from ¥0.44 in the previous year[25] - The total comprehensive income attributable to the parent company for the first three quarters of 2025 was ¥459,603,789.62, a decrease from ¥514,800,610.01 in 2024[25] Assets and Liabilities - Total assets at the end of the quarter were ¥15,317,639,964.13, a decrease of 4.10% from the end of the previous year[5] - The company's total assets decreased to ¥15,317,639,964.13 from ¥15,972,478,068.00, a decline of approximately 4.09%[21] - Total liabilities decreased to ¥6,562,369,900.01 from ¥7,393,464,632.58, representing a reduction of about 11.24%[20] - The equity attributable to shareholders increased to ¥8,510,481,174.57, up 2.03% from the end of the previous year[5] - The company's equity attributable to shareholders increased to ¥8,510,481,174.57 from ¥8,341,353,163.16, showing an increase of approximately 2.03%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,644,663,551.07, an increase of 12.99%[4] - Net cash flow from operating activities for the first three quarters of 2025 was ¥1,644,663,551.07, compared to ¥1,455,579,860.77 in 2024, indicating an increase of about 12.9%[28] - The company reported a net cash outflow from investing activities of ¥198,673,150.61 in 2025, worsening from a net outflow of ¥120,299,452.25 in 2024[28] - Cash and cash equivalents at the end of Q3 2025 amounted to ¥1,392,479,467.78, up from ¥1,193,265,560.31 at the end of Q3 2024[29] - The company's cash and cash equivalents decreased to ¥51,258,502.22 from ¥69,771,512.72, a decline of approximately 26.66%[21] - As of September 30, 2025, the company's cash and cash equivalents amounted to RMB 1,516,606,462.28, an increase from RMB 1,497,647,788.41 at the end of 2024[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 54,361[11] - Zhejiang Haizheng Group Co., Ltd. holds 320,783,590 shares, accounting for 26.76% of the total shares[11] - The company has repurchased 35,711,300 shares, representing 2.98% of the total share capital, for future employee stock ownership plans[12] - The top ten shareholders include state-owned enterprises, with Zhejiang Haizheng Group being the largest shareholder[11] - The company has not identified any related party transactions among its shareholders[12] Expenses and Investments - Research and development expenses increased to ¥372,154,095.37 from ¥262,633,894.43, indicating a rise of about 41.73%[23] - The company reported a significant increase in sales expenses, which rose to ¥1,609,805,985.09 from ¥1,583,085,460.85, an increase of about 1.69%[23] - The company experienced a loss in investment income of ¥34,534,648.03 compared to a gain of ¥181,056,163.81 in the previous year[24] - The company plans to invest RMB 50 million in Nanjing Jisheng Aoma Biopharmaceutical Co., Ltd., holding 10.9890% of its shares[14] - The company has completed the transfer of shares to Growth River Investment Limited and Empire Gateway Investment Limited as part of a settlement agreement[13] Non-Recurring Items - Non-recurring gains and losses for the quarter totaled -¥7,428,970.04, with significant impacts from various adjustments and losses[8] - The company experienced a decrease in tax refunds received, totaling ¥13,156,921.23 in 2025 compared to ¥51,151,542.76 in 2024[27] - Cash inflow from financing activities in 2025 was ¥1,431,330,849.25, significantly lower than ¥3,452,000,000.00 in 2024[28] - The company paid out ¥323,720,682.87 in dividends and interest in 2025, compared to ¥112,231,571.14 in 2024, indicating a substantial increase in cash outflows[28] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥231,228.83 in 2025, compared to a positive impact of ¥2,597,714.07 in 2024[28]